The dazzling success of weight-loss drugs in the United States is leading to lower interest rates in Denmark, home of one of their biggest manufacturers, according to the Nordic country's biggest b...

Ozempic is practically flying off the shelves to treat diabetes and obesity. The drug could also be useful in reducing cardiac event risk, per a new study.

Weight-loss drugs are substantially more expensive in the US than in other comparably large, high-income countries, according to a new analysis from the health policy organization KFF. The analysis...

The results complement the data Novo Nordisk released last week, which found Wegovy slashed the risk of serious heart problems and heart-related death by 20%.

Novo Nordisk (NVO) continues to witness increasing demand for its diabetes and obesity care products like Ozempic, Wegovy and Rybelsus amid rising competition from other pharma bigwigs.

Novo Nordisk rose on news of encouraging outcomes for its SELECT trial of weight loss drug semaglutide. The Danish pharmaceutical leader also raised its full-year sales and profit outlook after pos...

Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Novo Nordisk (NYSE:NVO) has raised its full-year outlook based on a strong first half of 2023 driven by continued high demand for its popular weight-loss drug Wegovy. The Denmark-headquartered glob...

Novo Nordisk raised its outlook as revenue from its popular weight-loss treatment, Wegovy, skyrocketed.

Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down Novo Nordisk's Q2 earnings which included profit up 43% and sales up 30%.

Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.

Inversago's drugs use a different approach than most treatments in the obesity and diabetes space.

Novo Nordisk hopes to show additional health benefits from taking its hugely popular drug Wegovy, apart from losing weight and cutting the risk of heart disease, its drug development executive told...

Novo Nordisk expects new data showing the heart benefits of its weight-loss drug Wegovy will help its discussions with public health authorities and other payers about the benefits of paying for it...

Novo Nordisk's limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will likely last into next year, CEO Lars Fruergaard Jorgensen told Reuters on Thursday.